Talis Biomedical Corporation (TLIS)

USD 1.84

(3.37%)

Market Cap (In USD)

3.35 Million

Revenue (In USD)

412 Thousand

Net Income (In USD)

-62 Million

Avg. Volume

28.29 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.37-9.6
PE
-
EPS
-
Beta Value
1.561
ISIN
US87424L2079
CUSIP
87424L108
CIK
1584751
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Devices
CEO
Mr. Robert Kelley MBA
Employee Count
-
Website
https://talisbio.com
Ipo Date
2021-02-12
Details
Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.